Safety of SGLT2 inhibitors versus DPP-4 inhibitors in super-elderly patients (≥ 80 years) with type 2 diabetes: a propensity score-matched cohort study.
SGLT2 inhibitors appear safer than alternative diabetes drugs for very elderly patients, with evidence suggesting lower mortality risk across multiple safety measures.
Large real-world propensity-matched analysis demonstrates SGLT2 inhibitors are safer than DPP-4 inhibitors in super-elderly T2DM patients across most adverse outcome domains. The mortality benefit (HR 0.73) and consistent safety profile across medication subgroups provides strong clinical evidence for SGLT2i use in this age group.
What the study was
- Study design
- Propensity score-matched retrospective cohort
- Population
- Super-elderly (≥80 yr) T2DM patients; n=65,119 propensity-matched pairs from TriNetX
- Sample size
- 65119
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Cardiovascular diabetology. Endocrinology reports
Why it surfaced
Large propensity-matched cohort (n=65,119); mortality + multi-domain safety benefit in super-elderly T2DM; directly actionable for geriatric prescribers.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.